Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Brian, If you are reading this board

SGE,

You say 

"One would resonably assume, with what all PTSC had/has going for it, that the retail demand would be more than sufficient to overcome S&L's sell strategy."

and then say

 "What if PTSC pushed the PR button? Well, then would be viewed as a pump and dump scheme (and it would be, with S&L doing the dumping)."

 

How will there be a retail demand without PTSC pushing the "PR button"? Are you suggesting that retail investors should have purchased PTSC shares with confidence despite the clound of uncertainty that surrounded the trial with J3/ARM?

 

Share
New Message
Please login to post a reply